These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 26298553)

  • 1. Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification (Part II): Psychiatric complaints and their relation to delta-9-tetrahydrocannabinol and its metabolites in serum.
    Bonnet U; Borda T; Scherbaum N; Specka M
    Drug Alcohol Depend; 2015 Oct; 155():302-6. PubMed ID: 26298553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification: cannabis withdrawal syndrome and its correlation with delta-9-tetrahydrocannabinol and -metabolites in serum.
    Bonnet U; Specka M; Stratmann U; Ochwadt R; Scherbaum N
    Drug Alcohol Depend; 2014 Oct; 143():189-97. PubMed ID: 25127704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.
    Milman G; Bergamaschi MM; Lee D; Mendu DR; Barnes AJ; Vandrey R; Huestis MA
    Ther Drug Monit; 2014 Apr; 36(2):218-24. PubMed ID: 24067260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Heavy Recreational Cannabis Use and Serum Delta-9-Tetrahydrocannabinol Levels are not Associated with an Impaired Liver Function in Cannabis Dependents.
    Bonnet U; Canbay A; Specka M; Scherbaum N
    J Psychoactive Drugs; 2018; 50(4):355-360. PubMed ID: 30052163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance.
    Karschner EL; Swortwood MJ; Hirvonen J; Goodwin RS; Bosker WM; Ramaekers JG; Huestis MA
    Drug Test Anal; 2016 Jul; 8(7):682-9. PubMed ID: 26097154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of cannabis use on inpatient psychiatric hospital outcomes.
    Rylander M; Winston HR; Medlin H; Hull M; Nussbaum A
    Am J Drug Alcohol Abuse; 2018; 44(1):73-84. PubMed ID: 28613973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls.
    Rabin RA; Barr MS; Goodman MS; Herman Y; Zakzanis KK; Kish SJ; Kiang M; Remington G; George TP
    Neuropsychopharmacology; 2017 Oct; 42(11):2259-2271. PubMed ID: 28443616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proof of active cannabis use comparing 11-hydroxy-∆9-tetrahydrocannabinol with 11-nor-9-carboxy-tetrahydrocannabinol concentrations.
    Franz T; Skopp G; Schwarz G; Musshoff F
    Drug Test Anal; 2018 Oct; 10(10):1573-1578. PubMed ID: 29845743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma and urine profiles of Delta9-tetrahydrocannabinol and its metabolites 11-hydroxy-Delta9-tetrahydrocannabinol and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes.
    Brenneisen R; Meyer P; Chtioui H; Saugy M; Kamber M
    Anal Bioanal Chem; 2010 Apr; 396(7):2493-502. PubMed ID: 20112012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial.
    Müller-Vahl KR; Schneider U; Koblenz A; Jöbges M; Kolbe H; Daldrup T; Emrich HM
    Pharmacopsychiatry; 2002 Mar; 35(2):57-61. PubMed ID: 11951146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Driving Under the Influence of Marijuana Versus Driving and Dying Under the Influence of Marijuana: A Comparison of Blood Concentrations of Δ9-Tetrahydrocannabinol, 11-Hydroxy-Δ9-Tetrahydrocannabinol, 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol and Other Cannabinoids in Arrested Drivers Versus Deceased Drivers.
    Lemos NP; San Nicolas AC; Volk JA; Ingle EA; Williams CM
    J Anal Toxicol; 2015 Oct; 39(8):588-601. PubMed ID: 26378132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual cannabis levels in blood, urine and oral fluid following heavy cannabis use.
    Odell MS; Frei MY; Gerostamoulos D; Chu M; Lubman DI
    Forensic Sci Int; 2015 Apr; 249():173-80. PubMed ID: 25698515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?
    Curran HV; Hindocha C; Morgan CJA; Shaban N; Das RK; Freeman TP
    Psychol Med; 2019 Jul; 49(9):1574-1580. PubMed ID: 30176957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic cannabis abuse, delta-9-tetrahydrocannabinol and thyroid function.
    Bonnet U
    Pharmacopsychiatry; 2013 Jan; 46(1):35-6. PubMed ID: 22821384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Separate and combined effects of the cannabinoid agonists nabilone and Δ⁹-THC in humans discriminating Δ⁹-THC.
    Lile JA; Kelly TH; Hays LR
    Drug Alcohol Depend; 2011 Jul; 116(1-3):86-92. PubMed ID: 21227600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws.
    Bergamaschi MM; Karschner EL; Goodwin RS; Scheidweiler KB; Hirvonen J; Queiroz RH; Huestis MA
    Clin Chem; 2013 Mar; 59(3):519-26. PubMed ID: 23449702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.
    Herrmann ES; Cooper ZD; Bedi G; Ramesh D; Reed SC; Comer SD; Foltin RW; Haney M
    Psychopharmacology (Berl); 2016 Jul; 233(13):2469-78. PubMed ID: 27085870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study.
    van der Pol P; Liebregts N; Brunt T; van Amsterdam J; de Graaf R; Korf DJ; van den Brink W; van Laar M
    Addiction; 2014 Jul; 109(7):1101-9. PubMed ID: 24628797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary excretion half-life of delta 1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking.
    Johansson E; Halldin MM
    J Anal Toxicol; 1989; 13(4):218-23. PubMed ID: 2550702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of phase II metabolism of 11-hydroxy-Δ-9-tetrahydrocannabinol and metabolite verification by chemical synthesis of 11-hydroxy-Δ-9-tetrahydrocannabinol-glucuronide.
    Hassenberg C; Clausen F; Hoffmann G; Studer A; Schürenkamp J
    Int J Legal Med; 2020 Nov; 134(6):2105-2119. PubMed ID: 32808050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.